









Markets
/
Stocks
/
nasdaq-cntb
/

Connect Biopharma Holdings Ltd

CNTB



View Detailed Chart

2.400USD

+0.130+5.73%

Market hours （ET）Quotes delayed by 15 min

133.89MMarket Cap

LossP/E TTM



Connect Biopharma Holdings Ltd

2.400

+0.130+5.73%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+5.73%

5 Days

-4.00%

1 Month

-21.05%

6 Months

+133.01%

Year to Date

+73.91%

1 Year

+152.39%

View Detailed Chart

TradingKey Stock Score of Connect Biopharma Holdings Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Connect Biopharma Holdings Ltd's Score

Industry at a Glance

Industry Ranking

244 / 501

Overall Ranking

437 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

7.900

Target Price

+227.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Connect Biopharma Holdings Ltd Highlights

StrengthsRisks

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.03M.

Overvalued

The company’s latest PE is -1.91, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.65M shares, decreasing 14.81% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 143.70K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.04.